TICKERNERD
Menu
BDXBDXHealthcare · Medical Instruments & Supplies

BDX Stock Forecast: Becton, Dickinson & Co. Price Predictions for 2026-2027

Last close, 9 Sept 2026
$180
+0.39% on the day

The 14 Wall Street analysts covering Becton, Dickinson & Co. hold a median 12-month price target of $198 — +9.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 8 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$48.8B
Ticker Nerd rank
93 / 100
Median analyst target
$198
Analysts covering
14
Revenue$5.0B−9.5% y/y
Operating income$752.0M
Net income$377.0M
Free cash flow$508.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.9%
1M
+1.7%
YTD
+19.4%
1Y
+22.5%
From 52W high
−6.4%
From 52W low
+32.3%
$136
$192
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Becton, Dickinson & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
98
Volatility
97
Value
94
Revisions
80
Accruals
78
Momentum
72
Quality
70
Growth
40
Size
5

Issuance (98): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (40): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (5): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$140$160$180$200$220$240Oct 25Jan 26Apr 26Jul 26BDXHigh $225Median $198Low $170

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
7 Buy7 Hold0 Sell
Low $170Median $198High $225

The green dot is the last close — the median target sits +9.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
31 Aug 2026B of A SecuritiesMaintainsNeutral$185 → $200
13 Aug 2026RBC CapitalMaintainsSector Perform$180 → $190
13 Aug 2026RBC CapitalMaintainsSector Perform—
7 Aug 2026CitigroupMaintainsBuy$198 → $204
7 Aug 2026CitigroupMaintainsBuy—
7 Aug 2026Piper SandlerMaintainsNeutral$161 → $175
7 Aug 2026Piper SandlerMaintainsNeutral—
7 Aug 2026RBC CapitalMaintainsSector Perform$175 → $180
7 Aug 2026RBC CapitalMaintainsSector Perform—
7 Aug 2026Wells FargoMaintainsEqual-Weight$161 → $170
7 Aug 2026Wells FargoMaintainsEqual-Weight—
5 Aug 2026TD CowenMaintainsHold—
5 Aug 2026TD CowenMaintainsHold$163 → $182
28 July 2026UBSInitiatesBuy—
28 July 2026UBSInitiatesBuy$190
6 July 2026Evercore ISI GroupMaintainsOutperform—
6 July 2026Evercore ISI GroupMaintainsOutperform$190 → $180
11 May 2026BarclaysMaintainsOverweight—
8 May 2026Wells FargoMaintainsEqual-Weight—
4 May 2026TD CowenMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BDX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BDX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, Becton, Dickinson & Co. returned +22.5% against +18.5% for the S&P 500, dividends included.

BDX vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Oct 25Jan 26Apr 26Jul 26BDXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.7%
Analysts raising
11
Analysts cutting
0
Fundamentals

Becton, Dickinson & Co. (BDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
31.0×

Cheaper than 25% of US stocks

Price / sales
2.2×

Cheaper than 51% of US stocks

Price / book
2.0×

Cheaper than 47% of US stocks

EV / EBITDA
10.9×

Cheaper than 36% of US stocks

Growth & margins
Revenue growth (YoY)
5.4%

Higher than 40% of US stocks

Earnings growth (YoY)
−34.3%

Higher than 15% of US stocks

Gross margin
46.5%

Higher than 58% of US stocks

Operating margin
15.7%

Higher than 74% of US stocks

Net margin
4.2%

Higher than 58% of US stocks

Returns & dividend
Return on equity
6.6%

Higher than 56% of US stocks

Return on assets
4.3%

Higher than 73% of US stocks

Dividend yield
2.3%

Higher than 52% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Becton, Dickinson & Co. (BDX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Becton, Dickinson & Co. has a market value of $48.8B and an enterprise value of $66.4B.

  • Revenue in the twelve months to 30 June 2026: $20.8B. The latest quarter grew 5.4% year on year.

  • Net income over the same four quarters: $941.0M, a 4.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $2.5B, after $728.0M of capital spending.

  • Becton, Dickinson & Co. spent $1.2B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 272.4M.

  • Trailing P/E: 31.0×; forward P/E: 13.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.34%, paying out 72% of earnings.

  • Becton, Dickinson & Co. employs 72,000 people — $289K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Sept 2026

Data provided by Twelve Data

Peers

BDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
BDXBecton, Dickinson & Co.$48.8B
93
MDLNMedline, Inc.$45.6B
19
ALCAlcon AG$34.4B
69
RMDResMed, Inc.$32.3B
70
WSTWest Pharmaceutical Services, Inc.$24.3B
93
ISRGIntuitive Surgical, Inc.$125.5B
73
SOLVSolventum Corp.$15.6B
89

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Becton, Dickinson & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BDX news & analysis

Becton, Dickinson and Company (BDX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha · 9 Sept 2026neutral

Becton, Dickinson and Company presented at the Wells Fargo 21st Annual Healthcare Conference, with a transcript of the event published on Seeking Alpha. The presentation covered the company's participation in the conference.

Why it matters — BDX watchers can review the conference transcript for management's remarks and any insight shared during the presentation.

Two Recessions Couldn't Stop These 4 Healthcare Stocks From Raising Dividends

24/7 Wall Street · 31 Aug 2026positive

The article highlights healthcare companies that continued raising their dividends through every quarter of two severe recessions, periods during which many other companies cut or eliminated payouts.

Why it matters — A BDX watcher would care because the piece showcases dividend resilience in the healthcare sector through economic downturns, which bears on the stability BDX and its peers have shown.

Jim Cramer Calls This Mining Stock an Inflation Hedge “Just as Good as Crypto”

24/7 Wall Street · 31 Aug 2026neutral

On CNBC's Mad Money Lightning Round, Jim Cramer answered viewer questions, advising buying Vale (NYSE:VALE) as an inflation hedge he likened to cryptocurrency and recommending staying long Apple (NASDAQ:AAPL) through an upcoming leadership change.

Why it matters — This report does not mention Becton, Dickinson & Co., so it offers no direct company-specific information for BDX watchers beyond general market commentary.

BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation

PRNewsWire · 27 Aug 2026positive

BD announced that its STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture has surpassed a key enrollment milestone, advancing clinical evaluation as part of its advanced tissue regeneration strategy.

Why it matters — A BDX watcher would care because this milestone signals progress in generating clinical evidence for GalaFLEX LITE™ Scaffold, a key product in BD's advanced tissue regeneration and expansion efforts.

BD to Present at Wells Fargo 21st Annual Healthcare Conference

PRNewsWire · 26 Aug 2026neutral

BD (Becton, Dickinson and Company) announced it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. The presentation was announced from Franklin Lakes, N.J.

Why it matters — The presentation gives BDX watchers an opportunity to hear directly from the company's management at a major healthcare investment conference.

FAQ

Frequently asked questions about BDX stock

What is the BDX stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Becton, Dickinson & Co. have a median 12-month price target of $198, with estimates ranging from $170 to $225. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BDX stock a buy right now?

Of the 14 analysts covering Becton, Dickinson & Co., 7 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Becton, Dickinson & Co. 93 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BDX?

As at 8 Sept 2026, Becton, Dickinson & Co. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (98 of 100).

Will BDX stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +9.8% from the last close, and Ticker Nerd's factor model ranks Becton, Dickinson & Co. 93 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BDX stock forecast for 2030?

No analyst covering Becton, Dickinson & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $170 to $225 over the next 12 months.

How has BDX stock performed over the past year?

Becton, Dickinson & Co. returned +22.5% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Becton, Dickinson & Co. do?

Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells a broad range of products used across healthcare and life sciences. Becton, Dickinson and Company serves hospitals, physicians, clinical laboratories, researchers, and public health organizations with medical supplies, diagnostic systems, laboratory equipment, and interventional devices.

What is the latest news on BDX?

The most recent item we track (Seeking Alpha, 9 Sept 2026): "Becton, Dickinson and Company (BDX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript". Becton, Dickinson and Company presented at the Wells Fargo 21st Annual Healthcare Conference, with a transcript of the event published on Seeking Alpha. The presentation covered the company's participation in the conference.

Company

About Becton, Dickinson & Co.

Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells a broad range of products used across healthcare and life sciences. Becton, Dickinson and Company serves hospitals, physicians, clinical laboratories, researchers, and public health organizations with medical supplies, diagnostic systems, laboratory equipment, and interventional devices. Its current business centers on medical essentials, connected care, biopharma systems, and interventional products, supporting workflows such as specimen handling, medication delivery, infection prevention, vascular access, and surgical procedures. The company’s portfolio also includes tools and technologies used in drug delivery, patient safety, and clinical research. Headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company plays an important role in enabling medical discovery, improving care delivery, and supporting routine operations in healthcare settings worldwide.

CEO Mr. Thomas E. Polen Jr. · 72,000 employees · United States · https://www.bd.com